Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuraxpharm Buys Glenmark’s Polish CNS Assets

Glenmark’s Jacek Sawicki Becomes Neuraxpharm’s Poland Manager

Executive Summary

Neuraxpharm has struck a deal to acquire Glenmark’s CNS portfolio in Poland. As part of the agreement, Glenmark’s Jacek Sawicki has been named as general manager of Neuraxpharm Polska and will lead a business that now incorporates Glenmark’s CNS commercial team.

You may also be interested in...



Neuraxpharm Targets Austria With Easypharm Deal

Neuraxpharm has opened a unit in Austria after snapping up local consumer healthcare specialist Easypharm.

Neuraxpharm Expands Into Portugal

Neuraxpharm is aiming to expand in the Portuguese market with its first commercial launch lined up for December. Javier Mercadé will be heading up the southern European region comprising Italy, Spain and now Portugal.

Neuraxpharm Buys Into Cannabidiol Business

Neuraxpharm has entered the cannabidiol arena by striking a deal to buy Switzerland’s STU, a developer and distributor of natural cannabidiol consumer products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel